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Abstract
Background: Congenital myasthenic syndromes (CMSs) are a group of inherited dis-
orders of neuromuscular transmission that may be presynaptic, synaptic, or postsyn-
aptic. Causative mutations have been identified in 4 breeds including the Labrador
Retriever, Jack Russell Terrier, Heideterrier, and Danish Pointing Dog.
Hypothesis/Objective: Clinical and genetic characterization of a neuromuscular dis-
order in Golden Retriever (GR) puppies.
Animals: Four GR puppies from California were evaluated for generalized muscle
weakness beginning at weaning. Biological specimens were collected from the
affected puppies, and familial information was obtained. Blood or buccal swabs were
obtained from 63 unaffected GRs.
Methods: Complete physical, neurological, electrodiagnostic, and histological evalua-
tions and biochemical quantification of muscle acetylcholine receptors were per-
formed. Polymerase chain reaction was used to amplify the 17 exons of COLQ, and
sequences were obtained by Sanger sequencing. Variant frequency was assessed in
unrelated GRs and a public database.
Results: Clinical, neurological, and electrodiagnostic evaluations confirmed a disorder
of neuromuscular transmission in a GR family. Sequencing of all exons and splice sites
of a primary candidate gene, COLQ, identified a point mutation that predicts an amino
acid substitution (G294R). The primary COLQ transcript was absent from affected
muscle samples. All affected puppies were homozygous for the mutation, which was
not detected outside this GR family or in other breeds.
Abbreviations: AChR, acetylcholine receptor; CHRNE, gene encoding the epsilon subunit of the nicotinic acetylcholine receptor; CMAP, compound muscle action potential; CMS, congenital
myasthenic syndrome; COLQ, gene encoding the collagenous tail of acetylcholinesterase; EMG, electromyography; GR, Golden Retriever; MG, myasthenia gravis; PCR, polymerase chain reaction.
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Conclusions and Clinical Importance: We confirmed the diagnosis of a CMS in GR
puppies and identified a novel COLQ mutation. The COLQ gene encodes the collage-
nous tail of acetylcholinesterase, the enzyme responsible for termination of skeletal
muscle contraction by clearing acetylcholine at the neuromuscular junction. Clinicians
and breeders should be aware of this CMS in GR puppies with an early onset of
weakness.
K E YWORD S
canine, myasthenia gravis, myopathy, neuromuscular junction
1 | INTRODUCTION
Congenital myasthenic syndrome (CMS) refers to a heterogenous
group of inherited disorders of neuromuscular transmission that may
be presynaptic, synaptic or post-synaptic.1 To date, 32 CMSs have
been described in people with autosomal recessive and autosomal
dominant modes of inheritance.2 Clinical signs of CMS in dogs usually
begin at weaning with progressive muscle weakness that is exacer-
bated by exercise. Unlike in acquired myasthenia gravis (MG) in dogs,
megaesophagus is not a common clinical feature.
Although the first clinical report of congenital MG in dogs was
published in 1974,3 only a few gene mutations causing CMS have
been identified. These include a missense mutation in the gene
encoding choline acetyltransferase in Danish Pointing dogs,4 a non-
synonymous mutation in the gene encoding the collagen-like tail of
the asymmetric acetylcholinesterase (COLQ) in Labrador Retrievers,5
and a deletion and nonsynonymous mutation in the gene encoding
the epsilon subunit of the nicotinic acetylcholine receptor (CHRNE) in
Jack Russell Terriers6 and in Heideterriers,7 respectively. Congenital
myasthenic syndromes also have been clinically described in Smooth
Fox terriers8,9 and English Springer Spaniels,10 but mutations have not
yet been described.
Over a 2-year period, 4 Golden Retriever (GR) puppies from Cali-
fornia were examined for neuromuscular weakness beginning at the
time of weaning. Other than exercise intolerance, the puppies were
clinically normal. Confirming a diagnosis of a CMS can be difficult, and
a presumptive diagnosis can be made from the age of onset, neurolog-
ical examination, electrodiagnostic testing, and muscle biopsy to rule
out other congenital neuromuscular diseases. Where available, genetic
testing can confirm the diagnosis. Identification of new CMSs and
development of new genetic tests would be useful for the diagnosis
of these disorders. Here we describe a novel COLQ mutation in GR
puppies associated with CMS.
2 | MATERIALS AND METHODS
2.1 | Animals
Four related GR puppies, 2 males and 2 females, ranging from 3 to
5 months of age, were evaluated. All puppies were from the same
breeder in Southern California. Parentage information and pedigrees
could be obtained for only 2 of the affected puppies. Unaffected GRs
(n = 63) had no known relationships with this family.
2.2 | Electrodiagnostic testing
One affected pup was anesthetized, and complete neuromuscular
examinations were performed including electromyography (EMG), mea-
surement of motor and sensory nerve conduction velocities, and mea-
surement of the compound muscle action potential (CMAP) after
repetitive nerve stimulation at 1, 3, 10, and 50 Hz using a Nicolet Viking
Select EMG/evoked potential system (Nicolet, Biomedical Inc, Madison,
WI). Insulated stainless steel needle electrodes were used for both
nerve stimulation and recording from muscle, and a platinum subdermal
electrode (Grass-Telefactor) was employed as a ground. Motor nerve
conduction velocity of the peroneal and ulnar nerves was determined
by dividing the distance between proximal and distal stimulation sites
by the difference in latency of the corresponding CMAP recorded from
the extensor digitorum brevis11 and palmar interosseous12 muscles,
respectively, after supramaximal stimulation (2 Hz stimulus rate,
0.2 millisecond stimulus duration). Sensory nerve conduction studies
were performed on the peroneal, ulnar, and radial nerves using previ-
ously described techniques.13,14 Amplitude (peak-to-peak) was mea-
sured from CMAPs, and percentages of decrement were calculated for
each repetition rate. Muscle (vastus lateralis, triceps brachii, and cranial
tibial) and nerve (peroneal nerve) biopsy specimens were collected from
the side opposite that used for electrodiagnostic testing.
2.3 | Histopathology, histochemistry, and
fluorescence microscopy
Diagnostic muscle biopsy specimens were collected under general
anesthesia after electrodiagnostic testing. Immediately after collection,
muscles were snap frozen in isopentane precooled in liquid nitrogen
and stored at −80C until further processing. Light microscopic evalua-
tion of histological and histochemical stains and reactions was per-
formed according to standard protocols15 and included hematoxylin
and eosin, modified Gomori trichrome, periodic acid Schiff, phosphory-
lase, esterase, myofibrillar ATPase reactions with preincubation pH of
9.8 and 4.3, reduced nicotinamide adenine dinucleotide-tetrazolium
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reductase, succinic dehydrogenase, acid and alkaline phosphatase,
and oil red O.
Specimens from the peroneal nerve were immersion fixed in 2.5%
glutaraldehyde in 0.1 M phosphate buffer before shipment to an
author's laboratory (G.D.S.). Upon receipt, nerves were postfixed in
1% aqueous osmium tetroxide for 3 to 4 hours and then dehydrated
in a graded alcohol series and propylene oxide. After infiltration with a
1:1 mixture of propylene oxide and araldite resin for 4 hours, nerves
were placed in 100% araldite resin overnight and then embedded in
fresh araldite resin. Thick sections (1 μm) were cut and stained with
paraphenylediamine before light microscopic evaluation.
For histochemical localization of motor end-plates, serial cryo-
sections (8 μm) were obtained from the external intercostal muscle of
1 affected GR collected at necropsy. In addition, archived frozen mus-
cle of a previously diagnosed Jack Russell Terrier with CMS caused by
end-plate acetylcholine receptor (AChR) deficiency (neuromuscular
disease control)6 and archived normal dog intercostal muscle (wild-
type control) were included. Sections from each dog were incubated
with the esterase reaction15 for identification of presumptive motor
end-plates or Alexa Fluor 594 α-bungarotoxin (1:1000, Molecular Pro-
bes) for localization of AChRs at the motor end-plate according to
published procedures.6 Serial sections were evaluated by light micros-
copy (esterase reaction) or fluorescent microscopy (red fluorescence)
followed by localization of staining for comparison.
2.4 | Sample collection and nucleic acid isolation
Muscle biopsy specimens were collected from an affected GR puppy,
and whole blood was obtained from all 4 affected puppies. Blood or
buccal swabs were obtained from unaffected GRs. Informed owner
consent was obtained before collection of all biologic samples, in
accordance with protocols approved by the Clemson University Insti-
tutional Review Board (IBC2008-17). Owner consent was obtained
for necropsy and postmortem tissue collection from 1 affected puppy
at University of California, Davis.
Genomic DNA was isolated from blood and buccal swabs using Gen-
tra Puregene Blood Kit (Qiagen, Germantown, Maryland) and from mus-
cle using the DNEasy Kit (Qiagen). Ribonucleic acid was extracted from
snap frozen muscle tissue from an affected dog using the ToTALLY RNA
kit (Ambion, Foster City, California). Canine testis RNA was obtained
from Zyagen (San Diego, California). All RNAs were treated with the
Turbo DNA-free kit (Invitrogen, Carlsbad, California), and cDNAs were
synthesized using an oligo dT primer and the RevertAid First Strand
cDNA Synthesis kit (Thermo Scientific, Pittsburg, Pennsylvania).
2.5 | Sequencing and genotyping
Polymerase chain reactions (PCRs) to amplify the 17 exons of genomic
COLQ were performed using previously described primers and proto-
cols.5 Primers to amplify the last 7 exons of the COLQ transcript were
designed with the forward primer (50 GGGCAGAAAGGTGAAATGGGT)
spanning the exon 10 and 11 junction and the reverse primer located in
exon 17 (50 ATGTGAAGTAGCGGCAGGAC). A constitutively expressed
gene (PSMB7) was used to ensure that cDNA was present. Amplicons
were reamplified using band-stab PCR. Products were purified using an
ExoSAP master mix consisting of 0.5 units of Exonuclease I (New
England BioLabs, Ipswich, Massachusetts) and 0.25 units of shrimp
alkaline phosphatase (SAP, Promega, Madison, Washington). Sequenc-
ing products were resolved on an ABI 3730XL DNA Analyzer (Applied
Biosystems, Foster City, California). The c.880 G>A variant was gen-
otyped in the remaining 3 affected puppies and 63 unaffected GRs
using Sanger sequencing. We further investigated the presence of the
variant in a variant call file containing single nucleotide polymorphisms
and small insertions and deletions identified in the genomes of 668
domestic dogs, including 20 purebred GR, and 54 wild canids.16 In silico
programs, PolyPhen-217 and CPD prediction tool,18 were used to assess
the impact of the variant.
2.6 | AChR quantification and antibody-bound AChR
Acetylcholine receptors were extracted from an external intercostal
muscle specimen collected at necropsy from an affected puppy using
a modification of a previously described procedure.19 The muscle
specimens were stored at −70C before homogenization and extrac-
tion of AChR in 2% Triton X-100. Solubilized AChRs were labeled by
incubation with an excess of 125I-α-bungarotoxin (125I-αbgt) followed
by sequential addition of high titer rat-anti-AChR antibody and precip-
itation with goat anti-rat immunoglobulin G (IgG). The precipitate was
pelleted, washed, and quantitated in a gamma counter. The amount of
AChR complexed with 125I-αbgt was quantified and expressed in
terms of moles of 125I-αbgt precipitated per gram of tissue. The con-
centration of in situ antibody-AChR complexes was determined by
precipitation with anti-dog IgG in the presence of normal dog serum.
Quantitative serum AChR antibody concentrations were determined
as previously described using an immunoprecipitation radioimmunoas-
say procedure.19
3 | RESULTS
3.1 | Clinical description
Four related puppies were presented over a 2-year period to the Uni-
versity of California Davis Veterinary Medical Teaching Hospital Neu-
rology/Neurosurgery Service for clinical evaluation of generalized
weakness since approximately 6-8 weeks of age. The pups occasion-
ally would have a burst of energy but would shortly thereafter sit or
lie down. No abnormalities were noted on physical examinations of
3 of the 4 puppies. One puppy was bilaterally cryptorchid with stridor
at rest that worsened with excitement or activity. This puppy also had
a history of regurgitation. On neurological examination, abnormalities
were restricted to an abnormal gait in all puppies. The pups were
ambulatory with a choppy gait that became shorter and stiffer with
continued walking to the point that the pups would lie down (Video
S1). The pups appeared to tire easily and sat down often during exam-
ination. Clinical signs were most consistent with generalized neuro-
muscular disease caused by neuropathy, myopathy, or disorder of
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neuromuscular transmission. Based on the young age and multiple
related animals affected, an inherited neuromuscular disorder was
considered most likely. CBC and serum biochemical analysis, including
serum creatine kinase activities, were within normal limits for puppies.
Thoracic radiographs were normal in 1 puppy. An edrophonium chlo-
ride challenge was performed in 2 dogs. In 1 dog, there was no clinical
response, and in the other dog the challenge resulted in rapid worsen-
ing of clinical signs to the point of collapse, with gradual improvement
over a few minutes to baseline.
All 4 puppies were treated with albuterol 0.5 mg PO q8h (0.02-
0.08 mg/kg), with clinical improvement reported by all owners. The
1 puppy with stridor noted on initial examination at 5 months of age
presented again at 11 months of age for acute airway obstruction.
Laryngeal examination confirmed laryngeal paralysis, and a left laryngeal
tieback surgery was performed. Two days after the surgery, the dog
developed aspiration pneumonia and died. Of the remaining puppies,
1 puppy was lost to follow-up at 7 months of age, and 2 puppies were
euthanized at 6 months of age. Necropsy was performed on the latter
2 puppies, and no histological abnormalities were found in peripheral
nerves, muscle, brain, spinal cord, or other organs.
3.2 | Electrodiagnostic testing
Abnormalities were restricted to a mild decrease in the amplitude of
the M wave, and a decremental response of the CMAP after repetitive
nerve stimulation. These findings were consistent with a disorder of
neuromuscular transmission (Figure 1). Biopsy specimens from the
vastus lateralis, triceps brachii, and cranial tibial muscles were col-
lected under anesthesia for histological evaluation.
3.3 | Muscle histology, histochemistry, and
fluorescence microscopy
No specific pathological changes were identified in the muscle or
peripheral nerve biopsy specimens that would support an underlying
myopathy or neuropathy. The esterase reaction identified several
F IGURE 1 A series of recordings obtained using various repetition rates (1, 3, 10, and 50 Hz) during a repetitive nerve stimulation study in
one affected dog. A 1-minute rest period was utilized between each train of stimuli. All frequencies resulted in decremental responses identical to
those associated with myasthenia gravis (a change in amplitude of 10% or greater between the first and subsequent responses). This was the case
even with a tetanizing stimulus of 50 Hz when pseudofacilitation (an incremental response in amplitude with little or no change in area) is a
typical finding in normal dogs
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abnormally large motor end-plates in the affected puppy compared to
control end-plates (Figure 2). Using fluorescent labeled α-bungarotoxin,
staining of motor end-plates for AChRs was decreased but not absent
in the affected puppy compared to control muscle (Figure 2).
3.4 | AChR quantification
The AChR concentration from 1 affected GR puppy was determined in
external intercostal muscle samples collected origin to insertion after
euthanasia. The AChR concentration was decreased at 0.11 pmol/g tis-
sue (reference range, 0.2-0.4 pmol/g tissue). Antibodies were not
detected against AChRs in muscle or in serum.
3.5 | Sequencing and genotyping
Because 1 affected puppy had a decreased (but not absent) concen-
tration of AChRs at the motor end-plates and did not improve after IV
administration of edrophonium chloride, we hypothesized that CMS
could be the result of an end-plate AChE deficiency and prioritized
COLQ as a candidate causal gene. Evaluation of pedigree information
from 2 affected puppies identified extensive inbreeding (Figure 3),
F IGURE 2 Esterase reaction for localization of motor end-plates and fluorescent labeled α-bungarotoxin for localization of acetylcholine
receptors (AChRs) in cryosections of muscle from a GR with CMS and archived control muscle. Esterase staining showed enlarged motor end-
plates (arrows with long tail) compared to control muscle (arrows with short tail). AChRs were decreased (red fluorescence) but not absent in the
affected puppy compared to control muscle, consistent with the biochemical findings. Dapi staining highlights muscle nuclei. Bar in lower right
figure = 50 μm for all images
F IGURE 3 Pedigree for two affected puppies (shaded) shows
extensive inbreeding. The affected puppies share a sire that is also the
grandsire on the maternal side for both puppies
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suggesting homozygosity for a recessive allele inherited identically by
descent. Sequences from 1 affected GR indicated that 16 of 17 COLQ
exons were concordant with the Boxer reference genome. Exon
13 harbored a G>A transition (chr23:27175559) in position c.880 of
COLQ. All 4 affected dogs were homozygous for the mutation. The
variant was absent from 83 GRs and 702 additional domestic dog and
wild canid genomes. The nucleotide change predicts the replacement
of a glycine with an arginine (G294R, Figure 4A) in a position con-
served across placental mammals (Figure 4B). PolyPhen-2 predicts the
variant to be benign likely because arginine is the wild-type residue in
some organisms (eg, wallaby, chicken). A second in silico prediction
program indicates that the arginine may be pathogenic in dogs but
compensated by additional COLQ amino acid changes in other organ-
isms (8.1% likelihood).18
The G>A transition changes a GG to AG within exon 13 that could
create a new splice acceptor site and lead to aberrant splicing. Amplifi-
cation and sequencing of partial cDNAs showed 2 isoforms in the
testis control: a primary signal containing all exons 11 through
17 (748 bp) and a minor signal that skips exon 13 (608 bp). Comple-
mentary DNAs from muscle tissues of an affected dog amplified only
the minor signal (Figure 5).
4 | DISCUSSION
We confirmed a novel CMS in GRs and identified a second mutation
in canine COLQ. Treatment of CMS can be difficult and requires treat-
ment specific to the gene mutated.20 Treatments used for primary
AChR deficiency may not be beneficial or may even be detrimental in
other forms of CMS.1 Because no response was observed to an
edrophonium chloride challenge and primary AChR deficiency was
not suspected, the puppy was treated with albuterol (0.05 mg/kg
PO q8h), a selective β2-adrenergic agonist that has been used in
human patients with CMS and end-plate acetylcholinesterase defi-
ciency.1,21,22 The owners reported dramatic improvement in clinical
signs in the short term, but eventually the clinical signs progressed
despite treatment, resulting in death or euthanasia in the 3 puppies
for which the outcome was known.
Clinical differences should be apparent between CMS caused by
variants in the COLQ and CHRNE genes. Although fatigability is present
with mutations in both genes, challenge with the short-acting choliner-
gic agonist edrophonium chloride or treatment with the longer acting
pyridostigmine bromide results in improved muscle strength in dogs
with the CHRNE mutation5 but no response or worsening of muscle
weakness after cholinergic agonists in dogs with the COLQ variant. In
end-plate AChR deficiency associated with mutations in CHRNE, the
safety margin of neuromuscular transmission is compromised by a
decreased response to acetylcholine because of low AChR content.
F IGURE 4 A, Chromatogram
from a small section of COLQ
exon 16 from a control GR (top)
and an affected GR (bottom). The
G>A mutation predicting a
Gly>Arg amino acid change is
indicated with a red asterisk
(*). B, A partial amino acid
sequence of COLQ surrounding
the predicted substitution is
shown from several species. The
Glycine (G) that is changed to an
Arginine in the affected GR
puppies is shown in bold and is
conserved across mammals but
not chicken or wallaby
F IGURE 5 Agarose gel electrophoresis of cDNA amplicons from
COLQ and a housekeeping control. The muscle of an affected GR
(M) lacks the primary 748 bp COLQ amplicon present in testis from a
control dog (T). N denotes a cDNA negative control. Selected
fragment sizes (in bp) for the molecular ladder are marked to the left
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Cholinergic agonists inhibit AChE and prolong the action of available
acetylcholine, thereby improving the safety margin of neuromuscular
transmission.1 The AChR content is only mildly decreased in COLQ vari-
ants, and no further benefit can be derived from increasing available
acetylcholine. The mechanism by which adrenergic agonists improve
neuromuscular transmission is not understood.1
Esterase histochemistry similarly localizes motor end-plates with var-
iants in both genes. Staining for AChRs with fluorescein labeled α-bgt,
however, was not detectable in dogs with the CHRNE mutation,5 and
was decreased but detectable compared to control muscle in the puppies
with the COLQ mutation. Consistent with this finding, the decremental
responses of the CMAP to repetitive nerve stimulation were more mar-
ked in the CHRNE mutation (decrements of the CMAP of up to 66%)5
compared to mild decreases in the dogs with the COLQmutation.
As found in the Labrador Retrievers4 and Devon Rex and Sphynx
cats23 with end-plate AChE deficiencies, the GR G>A transition cau-
ses a missense in the COOH-terminal domain. COLQ anchors the cat-
alytic subunits of asymmetric AChE to the synaptic basal lamina and
stops prolonged muscle contraction by clearing acetylcholine after
muscle contraction. The mutation may result in impaired protein-
protein interactions necessary for anchoring COLQ to the basal lamina
and may lead to the enlarged and widespread esterase staining found
at the motor end-plates of an affected dog (Figure 2).
The G>A transition in the GR creates a novel AG sequence within
exon 13 that we hypothesize could serve as a splice acceptor and
cause aberrant splicing. Amplification of cDNAs from affected muscle
did not identify abnormal transcripts but rather a complete lack of the
primary COLQ isoform. A minor isoform that lacks exon 13 was pre-
sent. This isoform, which creates a frameshift, also was present in the
control tissue and has been previously described in humans.24
The mechanism behind the absence of COLQ transcripts in the
affected dog remains unclear. If the G>A transition does create an
alternative splice acceptor, it would cause the loss of 140 nucleotides
and a frameshift, likely triggering nonsense-mediated decay. Alterna-
tively, our approach could have missed an intronic mutation that
impacts the cDNA before exon 11 and triggers nonsense-mediated
decay. Regardless of the mechanism, the lack of COLQ transcripts is
consistent with the severe CMS phenotype observed in the GRs.
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